STOK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Stoke Therapeutics Inc (STOK) is not a strong buy at this moment for a beginner investor with a long-term horizon. While there are positive catalysts such as analyst optimism and the potential of its lead drug zorevunersen, the pre-market price decline, lack of strong trading signals, and weak financial performance suggest a cautious approach. Holding or waiting for further developments would be prudent.
The MACD is negative and contracting, RSI is neutral at 50.246, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 33.477, with resistance at 36.392 and support at 30.563.
Analysts have raised price targets, with Canaccord and Guggenheim projecting $60 due to the potential of zorevunersen.
The drug shows promise as a disease-modifying therapy for Dravet syndrome, with significant market potential.
Clinical data published in NEJM reinforces the drug's efficacy.
Pre-market price decline of -0.30%.
Insider selling by the Chief Medical Officer, reducing direct ownership by 26.01%.
Weak financial performance in Q4 2025, with revenue dropping -93.80% YoY and net income at -$57.93M.
In Q4 2025, revenue dropped -93.80% YoY to $1.4M. However, net income improved by 452.70% YoY to -$57.93M, and EPS increased by 444.44% YoY to -0.98. Gross margin remained at 100%. Despite some improvement in losses, the financials remain weak overall.
Analysts are optimistic, with multiple firms raising price targets recently. Canaccord and Guggenheim project a $60 target, citing the potential of zorevunersen. Wolfe Research and Wedbush also maintain Outperform ratings, emphasizing the drug's clinical promise and market potential.
